GLP-1 receptor agonists × body weight & composition

Observational studyScientific reports2026

Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study.

Zuzana Miertová et al.PubMed ↗Publisher ↗

What the trial testedas reported · 56 people · 2026

No range given

Reported higher body weight & composition, no range given

+0.31percentage points

As reported

difference 0.31 %, no interval

No range given

Reported higher body weight & composition, no range given

+0.47percentage points

As reported

difference 0.47 %, no interval

Two numbers in the abstract

the abstract, start to end

achieved a weight loss of 6.45 ± 0.31% (p < 0.01) in 3 months of semaglutide therapy, and in the subgroup of 30 patients where semaglutide was administered for 6 months, weight loss was 11.35 ± 0.47% (p < 0.01).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Body weight & composition
0.31
Body weight & composition
0.47
GLP-1 receptor agonistsBody weight & composition
1 / 3

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42236900